230 related articles for article (PubMed ID: 10397535)
1. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.
Staprans S; Marlowe N; Glidden D; Novakovic-Agopian T; Grant RM; Heyes M; Aweeka F; Deeks S; Price RW
AIDS; 1999 Jun; 13(9):1051-61. PubMed ID: 10397535
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.
Spudich SS; Nilsson AC; Lollo ND; Liegler TJ; Petropoulos CJ; Deeks SG; Paxinos EE; Price RW
BMC Infect Dis; 2005 Nov; 5():98. PubMed ID: 16266436
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
[TBL] [Abstract][Full Text] [Related]
4. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.
Lanier ER; Sturge G; McClernon D; Brown S; Halman M; Sacktor N; McArthur J; Atkinson JH; Clifford D; Price RW; Simpson D; Torres G; Catalan J; Marder K; Power C; Hall C; Romero C; Brew B
AIDS; 2001 Apr; 15(6):747-51. PubMed ID: 11371689
[TBL] [Abstract][Full Text] [Related]
6. Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance.
Bestetti A; Presi S; Pierotti C; Bossolasco S; Sala S; Racca S; Carrera P; Lazzarin A; Cinque P
J Neurovirol; 2004; 10 Suppl 1():52-7. PubMed ID: 14982740
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.
Saavedra-Lozano J; Ramos JT; Sanz F; Navarro ML; de José MI; Martín-Fontelos P; Mellado MJ; Leal JA; Rodriguez C; Luque I; Madison SJ; Irlbeck D; Lanier ER; Ramilo O
Pediatr Infect Dis J; 2006 Dec; 25(12):1142-52. PubMed ID: 17133160
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.
Christo PP; Greco DB; Aleixo AW; Livramento JA
BMC Infect Dis; 2007 Dec; 7():147. PubMed ID: 18096083
[TBL] [Abstract][Full Text] [Related]
10. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.
Aweeka F; Jayewardene A; Staprans S; Bellibas SE; Kearney B; Lizak P; Novakovic-Agopian T; Price RW
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):39-43. PubMed ID: 9928728
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
12. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
Polis MA; Suzman DL; Yoder CP; Shen JM; Mican JM; Dewar RL; Metcalf JA; Falloon J; Davey RT; Kovacs JA; Feinberg MB; Masur H; Piscitelli SC
AIDS; 2003 May; 17(8):1167-72. PubMed ID: 12819518
[TBL] [Abstract][Full Text] [Related]
13. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
Friedl AC; Ledergerber B; Flepp M; Hirschel B; Telenti A; Furrer H; Bucher HC; Bernasconi E; Weber R;
AIDS; 2001 Sep; 15(14):1793-800. PubMed ID: 11579241
[TBL] [Abstract][Full Text] [Related]
14. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).
Thiébaut R; Morlat P; Jacqmin-Gadda H; Neau D; Mercié P; Dabis F; Chêne G
AIDS; 2000 May; 14(8):971-8. PubMed ID: 10853978
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
[TBL] [Abstract][Full Text] [Related]
16. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
Bellman PC
AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
Neumann AU; Tubiana R; Calvez V; Robert C; Li TS; Agut H; Autran B; Katlama C
AIDS; 1999 Apr; 13(6):677-83. PubMed ID: 10397562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
